Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $43 million versus the consensus estimate of $30.35 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.